Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) provided a corporate and operational update on July 9, 2026, highlighting positive six-month results from its First-in-Human (FIH) study that enable advancement to Group Two clinical surgeries. The company also launched a financing initiative to fund completion of the FIH study and accelerate commercialization activities.
The positive six-month follow-up data from Group One patients demonstrated encouraging safety and performance outcomes, with successful implantation procedures and favorable post-operative results. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Notably, one patient previously considered legally blind is now qualified to drive, reflecting meaningful improvements in vision and quality of life.
These clinical outcomes have provided the foundation for Ocumetics to advance to the second group of its FIH study. Group Two surgeries remain on track for the third quarter of 2026 in Mexico City, under the leadership of Principal Investigator Dr. Raphael Vasquez. All regulatory requirements necessary to proceed have been successfully completed.
The company has completed development of its next-generation solid-state accommodating intraocular lens, the Ocumetics Lens, which incorporates significant advancements in manufacturability, surgical performance and scalability. The redesigned lens features a one-piece design, eliminating internal interface materials and containing no air, water or oil. Manufacturing has commenced with German partner Amiplant GmbH, in preparation for Group Two surgeries.
To support the next phase of clinical development, Ocumetics launched a financing initiative, as detailed in a news release dated July 7, 2026. Proceeds are expected to fund completion of Group Two surgeries, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging, advance regulatory programs, and continue strategic partnership initiatives. The company conducted over 50 one-on-one meetings with institutional investors, family offices, and strategic industry participants at recent investor conferences.
Strategic commercialization discussions continue with four of the world's seven largest ophthalmic companies. Management has met with representatives from these organizations to introduce the Ocumetics technology platform, and several have expressed interest in reviewing additional clinical data after Group Two surgeries. Follow-up discussions are tentatively scheduled for early Q4 2026, following the availability of one-month patient results from Group Two.
Ocumetics believes these discussions validate the commercial potential of its lens to address a significant unmet need in vision restoration after cataract surgery. The company is focused on completing Group Two surgeries, advancing regulatory initiatives, and building strategic relationships to support long-term commercialization.
The company's progress marks an important value-creation phase, as President and CEO Dean Burns stated: "The past several months have marked one of the most productive periods in Ocumetics' history. With group two surgeries expected to commence during the third quarter of 2026, we believe the Company is entering an important value-creation phase as we continue to build long-term shareholder value."
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. Its dynamic intraocular lens is designed to fit within the eye's natural lens compartment, potentially eliminating the need for corrective lenses by allowing natural muscle activity to shift focus from distance to near.
